Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company's bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is being developed as a potential treatment for acute myeloid leukemia and MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors. Merus B.V. is headquartered in Utrecht, the Netherlands....
+See MoreSharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 12 September 2026
2025-09-28 10:10:51 Sunday ET

Stock Synopsis: With a new Python program, we use, adapt, apply, and leverage each of the mainstream Gemini Gen AI models to conduct this comprehensive fund
2017-10-15 07:38:00 Sunday ET

Ivanka Trump and Treasury Secretary Steven Mnuchin both press the case for GOP tax legislation as economic relief for the middle-class without substantial t
2018-07-27 10:35:00 Friday ET

Admitting China to the World Trade Organization (WTO) and other international activities seems ineffective in imparting economic freedom and democracy to th
2022-03-25 09:34:00 Friday ET

Corporate cash management The empirical corporate finance literature suggests four primary motives for firms to hold cash. These motives include the tra
2018-06-04 08:38:00 Monday ET

Microsoft acquires GitHub, a software development platform that has been widely shared-and-used by more than 28 million programmers worldwide. GitHub's
2017-12-13 06:39:00 Wednesday ET

The Federal Communications Commission (FCC) has decided its majority vote to dismantle rules and regulations of most Internet service providers (ISPs) that